

Daniel E Kaufmann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9320259/daniel-e-kaufmann-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

7,007
citations

38
h-index

83
g-index

87
ext. papers

8,908
ext. citations

13
avg, IF

5.36
L-index

#	Paper	IF	Citations
77	Single-Cell Multiparametric Analysis of Rare HIV-Infected Cells Identified by Duplexed RNAflow-FISH.. <i>Methods in Molecular Biology</i> , 2022 , 2407, 291-313	1.4	
76	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.. <i>Cell Reports</i> , 2022 , 38, 110429	10.6	6
75	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021 , 7, eabj5629	14.3	8
74	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.. <i>Cell Host and Microbe</i> , 2021 ,	23.4	15
73	A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses 2021 ,		19
72	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
71	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. <i>Cell Reports Medicine</i> , 2021 , 2, 100290	18	68
70	The Biobanque québécoise de la COVID-19 (BQC19)-A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. <i>PLoS ONE</i> , 2021 , 16, e0245031	3.7	4
69	Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. <i>Cell Host and Microbe</i> , 2021 , 29, 904-916.e6	23.4	6
68	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. <i>Cell Host and Microbe</i> , 2021 , 29, 1137-1150.e6	23.4	68
67	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. <i>Nature Medicine</i> , 2021 , 27, 659-667	50.5	52
66	Translocated microbiome composition determines immunological outcome in treated HIV infection. <i>Cell</i> , 2021 , 184, 3899-3914.e16	56.2	8
65	Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity. <i>Cell Reports</i> , 2021 , 36, 109643	10.6	2
64	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <i>Immunity</i> , 2021 , 54, 2143-2158.e15	32.3	37
63	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <i>Nature Medicine</i> , 2021 , 27, 2012-2024	50.5	53
62	Impact of cobas PCR Media freezing on SARS-CoV-2 viral RNA integrity and whole genome sequencing analyses. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 101, 115521	2.9	
61	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset 2021 ,		14

60	Daily variations of gut microbial translocation markers in ART-treated HIV-infected people. <i>AIDS Research and Therapy</i> , 2020 , 17, 15	3	8
59	Single-Cell Technologies Applied to HIV-1 Research: Reaching Maturity. <i>Frontiers in Microbiology</i> , 2020 , 11, 297	5.7	11
58	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. <i>EBioMedicine</i> , 2020 , 54, 102727	8.8	20
57	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 T Cells. <i>Journal of Virology</i> , 2020 , 94,	6.6	10
56	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. <i>Nature Medicine</i> , 2020 , 26, 222-227	50.5	50
55	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. <i>MBio</i> , 2020 , 11,	7.8	118
54	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020 , 27, 963-975.e5	23.4	16
53	Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. <i>PLoS Pathogens</i> , 2019 , 15, e1007619	7.6	104
52	An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Cell Host and Microbe</i> , 2019 , 25, 578-587.e5	23.4	59
51	Altered differentiation is central to HIV-specific CD4 T cell dysfunction in progressive disease. <i>Nature Immunology</i> , 2019 , 20, 1059-1070	19.1	45
50	Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2463-2479	15.9	3
49	Targeting Mitochondria to Revive Dysfunctional Regulatory T Cells. <i>Trends in Molecular Medicine</i> , 2019 , 25, 1-3	11.5	3
48	Tools for Visualizing HIV in Cure Research. <i>Current HIV/AIDS Reports</i> , 2018 , 15, 39-48	5.9	4
47	Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. <i>Virology</i> , 2018 , 515, 38-45	3.6	27
46	Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. <i>Retrovirology</i> , 2018 , 15, 18	3.6	50
45	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. <i>Journal of Immunology</i> , 2018 , 201, 971-981	5.3	36
44	5TRapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. <i>Frontiers in Immunology</i> , 2018 , 9, 628	8.4	11
43	Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development. <i>Viruses</i> , 2018 , 10,	6.2	5

42	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. <i>MBio</i> , 2018 , 9,	7.8	56
41	Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. <i>PLoS ONE</i> , 2017 , 12, e0186998	3.7	119
40	RNA flow cytometric FISH for investigations into HIV immunology, vaccination and cure strategies. <i>AIDS Research and Therapy</i> , 2017 , 14, 40	3	6
39	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. <i>Nature Protocols</i> , 2017 , 12, 2029-2049	18.8	34
38	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. <i>Cell Host and Microbe</i> , 2016 , 20, 368-380	23.4	113
37	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <i>EBioMedicine</i> , 2016 , 12, 208-218	8.8	45
36	CXCL13 is a plasma biomarker of germinal center activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 2702-7	11.5	204
35	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. <i>Journal of Virology</i> , 2016 , 90, 2021-30	6.6	38
34	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. <i>EBioMedicine</i> , 2016 , 3, 122-134	8.8	53
33	CD4 mimetics sensitize HIV-1-infected cells to ADCC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E2687-94	11.5	89
32	The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. <i>Journal of Virology</i> , 2015 , 89, 545-51	6.6	128
31	HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses. <i>Journal of Virology</i> , 2015 , 90, 2208-20	6.6	25
30	Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2015 , 90, 2993-3002	6.6	50
29	Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1. <i>Journal of Virology</i> , 2015 , 89, 4015-9	6.6	17
28	Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes. <i>PLoS Pathogens</i> , 2015 , 11, e1005285	7.6	66
27	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. <i>Journal of Virological Methods</i> , 2014 , 208, 107-14	2.6	53
26	Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. <i>Journal of Virology</i> , 2014 , 88, 2508-18	6.6	43
25	Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. <i>Cell Host and Microbe</i> , 2014 , 16, 711-21	23.4	114

24	High-throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry. <i>Nature Communications</i> , 2014 , 5, 5641	17.4	102
23	Distinctive features of CD4+ T cell dysfunction in chronic viral infections. <i>Current Opinion in HIV and AIDS</i> , 2014 , 9, 446-51	4.2	35
22	Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. <i>Journal of Immunology</i> , 2013 , 191, 540-4	5.3	117
21	In vitro assay to evaluate the impact of immunoregulatory pathways on HIV-specific CD4 T cell effector function. <i>Journal of Visualized Experiments</i> , 2013 , e50821	1.6	4
20	A Blueprint for HIV Vaccine Discovery. <i>Cell Host and Microbe</i> , 2012 , 12, 396-407	23.4	302
19	Role of PD-1 in HIV pathogenesis and as target for therapy. <i>Current HIV/AIDS Reports</i> , 2012 , 9, 81-90	5.9	99
18	CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. <i>Journal of Virology</i> , 2012 , 86, 6586-94	6.6	30
17	HIV-specific CD4 T cells and immune control of viral replication. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 174-80	4.2	76
16	Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. <i>Blood</i> , 2011 , 118, 965-74	2.2	119
15	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. <i>Nature Medicine</i> , 2010 , 16, 1147-51	50.5	344
14	PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. <i>Journal of Immunology</i> , 2009 , 182, 5891-7	5.3	189
13	IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. <i>Blood</i> , 2009 , 114, 346-56	2.2	205
12	Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. <i>Journal of Infectious Diseases</i> , 2008 , 197, 563-71	7	425
11	Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 362-7	4.2	39
10	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. <i>Nature Immunology</i> , 2007 , 8, 1246-54	19.1	411
9	Treatment interruption to boost specific HIV immunity in acute infection. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 21-5	4.2	5
8	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. <i>Nature</i> , 2006 , 443, 350-4	50.4	2001
7	Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. <i>Journal of Virology</i> , 2004 , 78, 4463-77	6.6	157

6	Limited durability of viral control following treated acute HIV infection. <i>PLoS Medicine</i> , 2004 , 1, e36	11.6	126
5	The value of preserving HIV-specific immune responses. <i>Journal of HIV Therapy</i> , 2003 , 8, 19-25		3
4	A Neanderthal OAS1 isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies		4
3	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality		5
2	Covid-19 vaccine immunogenicity in people living with HIV-1		5
1	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses		4